Announcements Trials
Browse Landscape

Phase

Phase 2 50Phase 3 31Phase NA 11Phase EARLY_PHASE1 10Phase 4 10Phase 2/3 9Phase 1 6Phase 1/2 4

Status

Completed 3Terminated 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 3Breast 1

Conditions

Multiple Myeloma 3Triple Negative Breast Neoplasms 1Neoplasms, Plasma Cell 1Breast Neoplasms 1

Interventions

pembrolizumab 410Cyclophosphamide 394Carboplatin 306Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 210Bevacizumab 209fludarabine 192Docetaxel 187Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 120Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Interventional × Aspirin × Clear all
NCT02834403 2023-12-15

L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients

The Methodist Hospital Research Institute

Phase 1/2 Completed
37 enrolled 20 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00790842 2018-10-24

PrE1003

PrECOG, LLC.

Phase 1/2 Terminated
63 enrolled 14 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01355705 2018-09-18

Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma

Stanford University

Phase 1/2 Completed
14 enrolled 9 charts
Plasma cell

Multiple Myeloma

NCT00833833 2016-04-27

MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma

Celgene Corporation

Phase 1/2 Completed
259 enrolled 31 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡